<< Back

Innocoll to Report Fourth Quarter 2015 Financial Results and Host Webcast and Conference Call on March 17, 2016

ATHLONE, Ireland, March 11, 2016 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL) (the “Company”), a global, commercial stage, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that it will report fourth quarter financial results before the open of U.S. financial markets on March 17, 2016. Innocoll management will host a webcast and conference call at 8:30 a.m. EDT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.innocollinc.com and will be archived there for 90 days. A telephone replay of the call will be available until midnight EDT on March 20, 2016 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13632174.

About Innocoll AG
Innocoll is dedicated to making better happen—better ways for patients to recover from surgeries and better ways to treat limb-threatening infections. We strive to engineer better medicines to help patients get better.

Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits.

Our robust, late-stage product pipeline is focused on addressing a number of significant unmet medical needs: INL-001, a bupivacaine-collagen bioresorbable implant (Phase III), is being studied to provide better postoperative analgesia; INL-002, a gentamicin-collagen topical matrix (Phase III), is being investigated as a topical treatment to better cure diabetic foot infections; and INL-003, a bioresorbable collagen film surgical adhesion barrier (approved ex-US), is scheduled to enter clinical trials in the US for the prevention of postsurgical adhesions.

Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, and Biomet. All of our native collagen products—from extraction/purification of type-1 collagen through final delivery form—are manufactured at our certified, integrated plant in Saal, Germany.

Innocoll is a global company operating in Europe and the US, with plans to further partner in other high-potential areas around the world.

For more information, please visit www.innocoll.com.

CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.

Pepe Carmona
Chief Financial Officer
(215) 983-3362
Jeannie Hsu Sorenson, M.D.
Vice President, Investor Relations
(314) 458-7355
Investor Contact:
Russo Partners, LLC
Robert E. Flamm, Ph.D.
(212) 845-4226

Innocoll AG